Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma

References

• Arndt CAS, Nascimento AG, Schroeder G, et al. (1998). Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide. Eur J Cancer 34:1224–9.
   PubMed Web of Science ®Google Scholar
• Arnold RD, Slack JE, Straubinger RM. (2004). Quantification of doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy. J Chromatogr B 808:141–52.
   PubMed Web of Science ®Google Scholar
• Augustinus DGK, Henrie Ètte WAB, Dew D, et al. (2001). Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin’s lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy. Radiother Oncol 58:251–5.
   PubMed Web of Science ®Google Scholar
• Binetruy-Tournaire R, Demangel C, Malavaud B, et al. (2000). Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 19:1525–33.
   PubMed Web of Science ®Google Scholar
• Celia C, Trapasso E, Cosco D, et al. (2009). Turbiscan lab® expert analysis of the stability of ethosomes® and ultradeformable liposomes containing a bilayer fluidizing agent. Colloids Surf B Biointerfaces 72:155–60.
   PubMed Web of Science ®Google Scholar
• Danhier F. (2016). To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release 244:108–21.
   PubMed Web of Science ®Google Scholar
• Dolecek TA, Propp JM, Stroup NE, Kruchko C. (2012). Cbtrus Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14:v1–49.
   PubMed Web of Science ®Google Scholar
• Donahue MJ, Blakeley JO, Zhou J, et al. (2008). Evaluation of human brain tumor heterogeneity using multiple T1-based MRI signal weighting approaches. Magn Reson Med 59:336–44.
   PubMed Web of Science ®Google Scholar
• Dong XY, Wang W, Qu H, et al. (2016). Targeted delivery of doxorubicin and vincristine to lymph cancer: evaluation of novel nanostructured lipid carriers in vitro and in vivo. Drug Deliv 23:1374–8.
   PubMed Web of Science ®Google Scholar
• Elias L, Portlock CS, Rosenberg SA. (1978). Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer 42:1705–10.
   PubMed Web of Science ®Google Scholar
• Fishman JB, Rubin JB, Handrahan JV, et al. (1987). Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res 18:299–304.
   PubMed Web of Science ®Google Scholar
• Gao H, Zhang S, Cao SJ, et al. (2014). Angiopep-2 and activatable cell-penetrating peptide dual-functionalized nanoparticles for systemic glioma-targeting delivery. Mol Pharm 11:2755–63.
   PubMed Web of Science ®Google Scholar
• Gong W, Wang ZY, Liu N, et al. (2011). Improving efficiency of adriamycin crossing blood brain barrier by combination of thermosensitive liposomes and hyperthermia. Biol Pharm Bull 34:1058–64.
   PubMed Web of Science ®Google Scholar
• Hofmeister CC, Jansak B, Denlinger N, et al. (2008). Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leukemia Res 32:1295–8.
   PubMed Web of Science ®Google Scholar
• Hu K, Li J, Shen Y, et al. (2009). Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release 134:55–61.
   PubMed Web of Science ®Google Scholar
• Kang T, Jiang M, Jiang D, et al. (2015). Enhancing glioblastoma-specific penetration by functionalization of nanoparticles with an iron-mimic peptide targeting transferrin/transferrin receptor complex. Mol Pharm 12:2947–61.
   PubMed Web of Science ®Google Scholar
• Kawasaki H, Taira N, Ichi T, et al. (2014). Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide followed by surgery for thymic carcinoma. EJSO 40:1151–5.
   PubMed Web of Science ®Google Scholar
• Khodarev NN, Yu J, Labay E, et al. (2003). Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 116:1013–22.
   PubMed Web of Science ®Google Scholar
• Kuang Y, An S, Guo Y, et al. (2013). T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. Int J Pharm 454:11–20.
   PubMed Web of Science ®Google Scholar
• Lee MS, Dees EC, Wang AZ. (2017). Nanoparticle-delivered chemotherapy: old drugs in new packages. Oncology (Williston Park, NY) 31:198–208.
   PubMed Web of Science ®Google Scholar
• Liang XJ, Chen C, Zhao Y, Wang PC. (2010). Circumventing tumor resistance to chemo-therapy by nanotechnology, multi-drug resistance in cancer. New York (NY): Humana Press, 446–88.
   Google Scholar
• Li MY, Li ZP, Yang Y, et al. (2016). Thermo-sensitive liposome co-loaded of vincristine and doxorubicin based on their similar physicochemical properties had synergism on tumor treatment. Pharm Res 33:1881–98.
   PubMed Web of Science ®Google Scholar
• Liu S, Guo Y, Huang R, et al. (2012). Gene and doxorubicin co-delivery system for targeting therapy of glioma. Biomaterials 33:4907–16.
   PubMed Web of Science ®Google Scholar
• Li XY, Zhao Y, Sun MG, et al. (2014). Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma. Biomaterials 35:5591–604.
   PubMed Web of Science ®Google Scholar
• Morton SW, Lee MJ, Deng ZJ, et al. (2014). A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci Signal 7:44.
   Web of Science ®Google Scholar
• Niu G, Chen X. (2010). Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets 11:1000–17.
   PubMed Web of Science ®Google Scholar
• Qu J, Zhang L, Chen Z, et al. (2016). Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy? Drug Deliv 23:3408–16.
   PubMed Web of Science ®Google Scholar
• Shaw TK, Mandal D, Dey G, et al. (2017). Successful delivery of docetaxel to rat brain using experimentally developed nanoliposome: a treatment strategy for brain tumor. Drug Deliv 24:346–57.
   PubMed Web of Science ®Google Scholar
• Shinde RL, Devarajan PV. (2017). Docosahexaenoic acid-mediated, targeted and sustained brain delivery of curcumin microemulsion. Drug Deliv 24:152–61.
   PubMed Web of Science ®Google Scholar
• Song S, Mao G, Du J, Zhu X. (2016). Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. Drug Deliv 23:1404–8.
   PubMed Web of Science ®Google Scholar
• Takemura G, Fujiwara H. (2007). Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49:330–52.
   PubMed Web of Science ®Google Scholar
• Williams SK, Greener DA, Solenski NJ. (1984). Endocytosis and exocytosis of protein in capillary endothelium. J Cell Physiol 120:157–62.
   PubMed Web of Science ®Google Scholar
• Wu M, Fan Y, Lv S, et al. (2016). Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Deliv 23:2720–5.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang YF, Xie XY, et al. (2015). Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery. Biomaterials 48:84–96.
   PubMed Web of Science ®Google Scholar
• Ying M, Zhan CY, Wang SL, et al. (2016). Liposome-based systemic glioma-targeted drug delivery enabled by all-D peptides. ACS Appl Mater Interfaces 8:29977–85.
   PubMed Web of Science ®Google Scholar
• Zhu S, Qian L, Hong M, et al. (2011). RGD-modified PEG-PAMAM-DOX conjugate: in vitro and in vivo targeting to both tumor neovascular endothelial cells and tumor cells. Adv Mater 23:H84–9.
   PubMed Web of Science ®Google Scholar